Stockscreener 앱 받기
34.61
0.70%
0.24
시간 외 거래:
34.60
-0.010
-0.03%
전일 마감가:
$34.37
열려 있는:
$34.04
하루 거래량:
2.11M
Relative Volume:
1.01
시가총액:
$5.62B
수익:
-
순이익/손실:
$-328.94M
주가수익비율:
-14.13
EPS:
-2.4487
순현금흐름:
$-266.00M
1주 성능:
-2.04%
1개월 성능:
-9.73%
6개월 성능:
+189.14%
1년 성능:
+368.65%
1일 변동 폭
$33.84
$35.17
1주일 범위
$33.84
$37.18
52주 변동 폭
$3.72
$43.73
코젠트 바이오사이언시스 Stock (COGT) Company Profile
명칭
Cogent Biosciences Inc
전화
617-945-5576
주소
275 WYMAN STREET, WALTHAM
Compare COGT vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
COGT
Cogent Biosciences Inc
|
34.61 | 5.58B | 0 | -328.94M | -266.00M | -2.4487 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.05 | 114.72B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
737.45 | 78.67B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
684.50 | 42.38B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.10 | 41.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
282.72 | 31.33B | 5.36B | 287.73M | 924.18M | 2.5229 |
코젠트 바이오사이언시스 Stock (COGT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-16 | 재개 | Jefferies | Buy |
| 2025-11-10 | 업그레이드 | Stifel | Hold → Buy |
| 2025-11-10 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2025-10-16 | 개시 | Stifel | Hold |
| 2025-09-03 | 개시 | Raymond James | Strong Buy |
| 2025-03-07 | 개시 | Scotiabank | Sector Outperform |
| 2024-12-11 | 다운그레이드 | Needham | Buy → Hold |
| 2024-02-26 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2024-02-08 | 개시 | Citigroup | Buy |
| 2023-12-11 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2023-12-08 | 개시 | JP Morgan | Overweight |
| 2023-04-28 | 개시 | Robert W. Baird | Outperform |
| 2023-03-27 | 재개 | H.C. Wainwright | Buy |
| 2022-12-14 | 개시 | Needham | Buy |
| 2022-06-28 | 개시 | Guggenheim | Buy |
| 2021-10-11 | 개시 | H.C. Wainwright | Buy |
| 2021-06-09 | 재개 | Jefferies | Buy |
| 2020-12-23 | 개시 | Piper Sandler | Overweight |
| 2020-10-14 | 개시 | Ladenburg Thalmann | Buy |
모두보기
코젠트 바이오사이언시스 주식(COGT)의 최신 뉴스
Cogent Biosciences stock climbs after FDA accepts key drug application - MSN
HC Wainwright Analysts Lift Earnings Estimates for COGT - MarketBeat
Is Cogent Biosciences (COGT) one of the best multibagger stocks to buy according to billionaires? - MSN
Analysts Offer Insights on Healthcare Companies: Cogent Biosciences (COGT) and Ascendis Pharma (ASND) - The Globe and Mail
What Cogent Biosciences (COGT)'s FDA Acceptance of Bezuclastinib NDA Means For Shareholders - Yahoo Finance
COGT Shares Climb After FDA Accepts Bezuclastinib NDA for Non-Advanced SM - Bitget
Technical Analysis: What is the long term forecast for Cogent Biosciences Inc stockMarket Sentiment Report & Free Expert Verified Stock Movement Alerts - baoquankhu1.vn
COGT Rise as FDA Accepts Bezuclastinib NDA in Non-Advanced SM - The Globe and Mail
COGT: Wedbush Reiterates Outperform Rating with $55 Price Target - GuruFocus
Cogent Biosciences (NASDAQ:COGT) Earns Outperform Rating from Wedbush - MarketBeat
Cinctive Capital Management LP Buys Shares of 111,058 Cogent Biosciences, Inc. $COGT - MarketBeat
Boothbay Fund Management LLC Cuts Holdings in Cogent Biosciences, Inc. $COGT - MarketBeat
Cogent Biosciences (COGT) Valuation In Focus After FDA Accepts Bezuclastinib NDA For Systemic Mastocytosis - simplywall.st
Raymond James Maintains Strong Buy for Cogent Biosciences (COGT) March 2026 - Meyka
FDA accepts Cogent’s drug filing for treatment of rare blood disorder - MSN
Jefferies Initiates Buy Rating for Cogent Biosciences (COGT) wit - GuruFocus
Cogent Biosciences assumed with a Buy at Jefferies - TipRanks
Cogent Biosciences Stock Climbs After FDA Accepts Key Drug Application - Benzinga
Why Is Cogent Biosciences Stock Surging Monday?Cogent Biosciences (NASDAQ:COGT) - Benzinga
Cogent Biosciences (NASDAQ:COGT) Now Covered by Analysts at Jefferies Financial Group - MarketBeat
Cogent Biosciences (NASDAQ:COGT) Shares Gap UpHere's Why - MarketBeat
Cogent Biosciences, Inc. shares surged 7.2% in pre-market trading after the U.S. Food and Drug Administration (FDA) officially accepted its new drug application for a rare disease treatment and will initiate the review process. - Bitget
Cogent Biosciences shares are trading higher ... - Benzinga
Cogent Biosciences (COGT) FDA Update on Bezuclastinib for NonAdv - GuruFocus
Cogent Biosciences Says FDA Accepted Marketing Application for Bezuclastinib in Non-Advanced Systemic Mastocytosis - marketscreener.com
Cogent Biosciences Announces FDA Acceptance of New Drug Application for Bezuclastinib in Patients with NonAdvanced Systemic Mastocytosis (NonAdvSM) - The Manila Times
Cogent Biosciences Announces FDA Acceptance Of New Drug Application For Bezuclastinib In Patients With Nonadvanced Systemic Mastocytosis (Nonadvsm) - TradingView
FDA sets Dec. 30 action date on new nonadvanced systemic mastocytosis drug - Stock Titan
HighVista Strategies LLC Acquires 179,219 Shares of Cogent Biosciences, Inc. $COGT - MarketBeat
Cogent Biosciences, Inc. $COGT Shares Acquired by Fairmount Funds Management LLC - MarketBeat
Cogent Biosciences Stock Climbs After FDA Accepts Key Drug Application - Sahm
Commodore Capital LP Increases Stock Position in Cogent Biosciences, Inc. $COGT - MarketBeat
Boone Capital Management LLC Takes $13.57 Million Position in Cogent Biosciences, Inc. $COGT - MarketBeat
Cogent Biosciences, Inc. (NASDAQ:COGT) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Is Cogent Biosciences (COGT) One of the Best Multibagger Stocks to Buy According to Billionaires? - Insider Monkey
Cogent Biosciences Touts Bezuclastinib Pivotal Wins, Eyes Up to Three FDA Filings and U.S. Launches - Yahoo Finance
Biotech Stock Up 365% as This $8 Million Investment Targets a Drug With 3 NDA Filings Planned - AOL.com
(COGT) Volatility Zones as Tactical Triggers - Stock Traders Daily
Cogent Biosciences (COGT) Valuation Check After New SUMMIT Trial Results For Bezuclastinib - Sahm
Will Cogent Biosciences Inc benefit from AI trends2025 Top Decliners & Real-Time Price Movement Reports - baoquankhu1.vn
JPMorgan raises Cogent Biosciences (COGT) PT to $67 on sector model update - MSN
Cogent Biosciences (COGT) advances bezuclastinib-sunitinib combination with breakthrough therapy designation (BTD) - MSN
Vanguard Group Inc. Has $111.40 Million Holdings in Cogent Biosciences, Inc. $COGT - MarketBeat
COGT Earnings History & Surprises | EPS & Revenue Results | COGENT BIOSCIENCES INC (NASDAQ:COGT) - ChartMill
Rafferty Asset Management LLC Purchases 57,139 Shares of Cogent Biosciences, Inc. $COGT - MarketBeat
Cogent Biosciences slips after upsized $200 mln equity offering - TradingView
Cogent Biosciences: Trio Of Approvals Beckon For Lead DrugStill Bullish (NASDAQ:COGT) - Seeking Alpha
A Look At Cogent Biosciences (COGT) Valuation After Recent Share Price Volatility - Yahoo Finance
Bezuclastinib SUMMIT Data Reframe Cogent Biosciences Mastocytosis Opportunity - Yahoo Finance
Analysts Offer Insights on Healthcare Companies: Aardvark Therapeutics, Inc. (AARD), Upstream Bio, Inc. (UPB) and Cogent Biosciences (COGT) - The Globe and Mail
Cogent Biosciences (COGT) Reveals Promising Results in Latest Be - GuruFocus
코젠트 바이오사이언시스 (COGT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.20%
0.06%
자본화:
|
볼륨(24시간):